{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Mechanical and Oral Antibiotic Bowel Preparation Versus No Bowel Preparation for Elective Colectomy"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients scheduled for elective colonic resection were randomised to either MOABP or NBP."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients scheduled for elective colonic resection were randomised to either MOABP or NBP."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients scheduled for elective colonic resection were randomised to either MOABP or NBP."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of mechanical and oral antibiotic bowel preparation (MOABP) compared to no bowel preparation (NBP) on surgical-site infections (SSIs) in patients undergoing elective colectomy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of SSI within 30 days post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to recruiters, treating physicians, surgeons, data collectors, and analysts."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 381 patients were randomised: 217 to right colectomy (106 MOABP, 111 NBP) and 164 to left colectomy (84 MOABP, 80 NBP)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "In right colectomy, SSI rates were 7% (MOABP) and 9% (NBP) (OR 0.71, 95% CI 0.26 to 1.95; P = 0.510). In left colectomy, SSI rates were 6% (MOABP) and 10% (NBP) (OR 0.57, 95% CI 0.18 to 1.82; P = 0.338)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant differences in overall morbidity or adverse events were observed."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT02652637"
      },
      "Funding": {
        "score": 1,
        "evidence": "Vatsatautien Tutkimuss\u00e4\u00e4ti\u00f6 Foundation, Mary and Georg Ehrnrooth\u2019s Foundation, Finnish Cancer Foundation, Helsinki University Research Funds."
      }
    },
    "total_score": 21,
    "max_score": 25
  },
  "model": "gpt-4o"
}